Table of Content
- Introduction: Undenatured Type II Collagen for Joint Supplements
- What Is Undenatured Type II Collagen?
- Why Native Structure Matters in Undenatured Type II Collagen
- Why Joint Health Is a Growing Opportunity for Nutraceutical Brands
- Clinical Evidence for Unstergen® Undenatured Chicken Collagen Type II
- Undenatured Type II Collagen vs Hydrolysed Collagen
- Why Chicken Sternum Cartilage Is an Important Source
- What Should Nutraceutical Formulators Look For?
- Formulation Opportunities for Joint Supplements
- From Ingredient to Product Differentiation
- Evidence-Led Marketing: How Brands Should Word Their Claims
- The Opportunity for Manufacturers and Brands
- Conclusion: Undenatured Type II Collagen for Joint Supplements
- Frequently Asked Questions (FAQs) About Undenatured Type II Collagen
- About Titan Biotech Ltd.: Undenatured Type II Collagen Manufacturer and Exporter
- References
Introduction: Undenatured Type II Collagen for Joint Supplements
Joint health products are no longer built only around glucosamine, chondroitin and ordinary collagen peptides. Shoppers now look for ingredients with a clear scientific rationale that can support mobility, comfort and healthy ageing, and nutraceutical brands in turn need ingredients that come with a defined biological explanation and evidence from human studies.
Undenatured Type II collagen is one ingredient that fits this brief.
Hydrolysed collagen is cut into small peptides during processing. Undenatured Type II collagen is handled so that key features of the native protein survive. The difference matters for joints, because Type II collagen is a main structural protein of articular cartilage.
Interest has been lifted by new human data. A randomised, double-blind, placebo-controlled proof-of-concept study from 2025, published in the International Journal of Research in Orthopaedics, tested Unstergen®, the undenatured chicken collagen Type II ingredient made by Titan Biotech Limited, in adults with osteoarthritis. Taking 40 mg per day for 90 days, participants did better than those on placebo for WOMAC, pain, quality of life and investigator-rated X-ray findings.
For nutraceutical companies, this makes undenatured Type II collagen a credible option for differentiated joint products.
What Is Undenatured Type II Collagen?
Collagen is the most plentiful protein in the body and gives structure to connective tissue, but each collagen type has its own location and job. Type II collagen is found mainly in articular cartilage, which is why it is so relevant to joint products.
Undenatured Type II collagen has been gently processed to keep the protein’s native structure instead of being broken apart by hydrolysis. That creates two distinct groups of collagen ingredients:
- Hydrolysed collagen: cut into small peptides, with a rationale built on peptides and amino acids that come from collagen.
- Undenatured Type II collagen: designed to hold on to its native structure and relevant antigenic sites, so it is thought to act differently from a product that only supplies amino acids as raw material.
For this reason, formulators should not treat the two as interchangeable just because both come from collagen.
Why Native Structure Matters in Undenatured Type II Collagen
Keeping the native structure intact is the defining feature of this ingredient.
Studies of native Type II collagen suggest an oral tolerance mechanism. Here the immune system meets collagen through the gut-associated lymphoid tissue, and the unstergen® paper describes contact with Peyer’s patches and a suggested drop in how strongly Type II collagen is recognised as a foreign antigen.
This route is very different from the nutritional logic behind standard collagen peptides.
For ingredient makers, it opens a positioning route. Rather than compete only in the crowded collagen peptide space, undenatured Type II collagen can be presented as a targeted functional ingredient for joint formulas.
Communication must still follow the evidence. Oral tolerance is a proposed mechanism, so it should not be turned into promises such as reversing cartilage damage or curing osteoarthritis.
Why Joint Health Is a Growing Opportunity for Nutraceutical Brands
Joint health is bound up with movement, physical function and quality of life. Ageing, inactive lifestyles, extra body weight, heavy activity and earlier joint stress all push people towards mobility products.
As a result, the category now reaches well beyond classic supplements. Typical product concepts include:
- Gummies
- Sachets
- Ready-to-mix drinks
- Functional powders
- Capsules and tablets
- Functional foods
- Sports and active-lifestyle supplements
- Healthy-ageing formulas
- Combination mobility products
For B2B brands, the aim is to combine clear science, simple dosing and ingredients with clinical support.
Undenatured Type II collagen is attractive here because the clinical work used small daily amounts, compared with the gram-level doses normally linked to collagen peptides.
Clinical Evidence for Unstergen® Undenatured Chicken Collagen Type II
The 2025 Unstergen® trial, reported in the International Journal of Research in Orthopaedics, is among the most useful recent papers for ingredient companies. It followed a randomised, double-blind, placebo-controlled proof-of-concept design. Read the published study.
Study Design and Participants
Of 51 adults with osteoarthritis who were screened, 48 enrolled and 45 were analysed at the end, made up of 31 on Unstergen® and 14 on placebo. All were aged 30 to 65 years, had osteoarthritis of the hip or knee and reported moderate pain at screening.
The treatment was 40 mg of Unstergen® once a day for 90 days.
Researchers tracked these outcomes:
- WOMAC score
- Pain Numerical Rating Scale (NRS)
- Quality of life using the EQ-5D-5L questionnaire
- Investigator-rated Global Rating of Change from X-ray images in a smaller cohort
- Safety checks, including blood count and liver and kidney tests
WOMAC Improvement
WOMAC, short for the Western Ontario and McMaster Universities Osteoarthritis Index, is a standard tool for scoring pain, stiffness and physical function in people with osteoarthritis.
After 90 days, the overall WOMAC score fell by 20.39% in the Unstergen® group against 7.24% with placebo, a statistically significant difference.
Each domain also improved:
- Pain: down by 16.05%
- Stiffness: down by 18.95%
- Physical function: down by 19.22%
The matching placebo figures were 6.18%, 4.17% and 8.56%.
For formulators this matters because the result is not limited to one subjective score. WOMAC covers three everyday aspects of osteoarthritis: pain, stiffness and physical function.
Pain Reduction
Pain is one of the strongest drivers of demand in joint health.
The Unstergen® group had a 37.77% fall in Pain NRS at 90 days, against 8.70% on placebo, which equals an average drop of 2.29 points from baseline. In the pain domain of the WOMAC questionnaire, 93.55% of Unstergen® participants reported less joint pain during activities such as walking and climbing stairs.
Findings like these give developers a clinical basis for presenting undenatured Type II collagen as a source of joint comfort and mobility support, within the rules of the target market.
Stiffness and Physical Function
Buyers now expect joint products to do more than manage pain.
In the study, the WOMAC stiffness domain dropped by 18.95% and physical function by 19.22% in the unstergen® group. Improvement in stiffness was reported by 70.97% of participants, and improvement in everyday physical activity by 67.74%.
This supports a wider B2B formulation story that runs from joint health to comfort, mobility, physical function and quality of life. Instead of building around a single symptom, formulators can think about a fuller mobility-support concept.
Quality of Life
Quality of life is an increasingly important endpoint for healthy-ageing and joint products.
At 90 days, 90.32% of participants in the Unstergen® group reported better quality of life, compared with 7.14% on placebo, a statistically significant gap. On its quality-of-life scale, symptoms fell by 40.34% with Unstergen® and 11.25% with placebo.
Such outcomes are relevant for products aimed at adults who want support for mobility and daily activity.
X-Ray Assessment as an Extra Endpoint
A smaller cohort of 12 participants also had their X-ray images compared by an investigator at baseline and after 90 days.
In this group, 87.50% of Unstergen® participants showed marked improvement on the investigator-rated Global Rating of Change. The average score was 2.88, whereas placebo averaged -0.25.
The finding is interesting for research but needs careful wording. It came from a very small subset, and the study was mainly a proof-of-concept design, so it cannot be taken as proof that the ingredient reverses structural changes in osteoarthritis.
For responsible B2B messaging, state that investigator-rated radiographic improvement was seen in the study cohort and steer clear of sweeping claims about cartilage regrowth.
Safety and Tolerability
Ingredients meant for long-term nutraceutical use need a sound safety record.
The study checked complete blood count and liver and kidney markers at the start and the end of the 90 days and found no significant differences. Six adverse events occurred, but the investigators judged them unrelated to the interventions. No serious adverse events were recorded, and no participant left the study because of one.
The authors therefore described a favourable safety profile over the 90-day period. Even so, the word safe should be read within the limits of the available evidence, not as an unlimited claim for every consumer group.
Undenatured Type II Collagen vs Hydrolysed Collagen
People often ask if undenatured Type II collagen ought to replace standard collagen peptides. In practice, the two meet different formulation goals.
| Parameter | Undenatured Type II Collagen | Hydrolysed Collagen |
|---|---|---|
| Processing | Processed to keep native structure | Broken down into small peptides |
| Molecular form | Structurally intact (native) | Peptides |
| Main positioning | Targeted joint support | General collagen peptide nutrition |
| Proposed mechanism | Oral tolerance pathway | Supply of peptides and amino acids |
| Usual inclusion | Low-dose functional ingredient | Typically a higher-dose ingredient |
| Key quality focus | Keeping native characteristics intact | Peptide profile and degree of hydrolysis |
This split helps brands design differentiated product lines. A formula centred on overall collagen peptide nutrition can use hydrolysed collagen, while a targeted joint formula can bring in undenatured Type II collagen as a specialised functional component.
Why Chicken Sternum Cartilage Is an Important Source
The clinical paper presents Unstergen® as an undenatured chicken Type II collagen taken from chicken sternum cartilage. The source is relevant since cartilage is a natural, rich supply of Type II collagen.
Still, using chicken cartilage does not make an ingredient equal to every other undenatured Type II collagen on the market. See the Unstergen® product page for details of this ingredient.
Procurement and development teams should look closely at:
- Raw material traceability
- Confirmation of Type II collagen identity
- Processing conditions
- Preservation of native structure
- Microbiological quality
- Contaminant and heavy metal limits
- Stability
- Consistency from batch to batch
- Certificate of Analysis (COA)
- Technical and regulatory documentation
- Clinical evidence behind the ingredient
Process control deserves special attention, because too much heat, chemical treatment or other harsh conditions can change protein structure.
Buyers sourcing undenatured Type II collagen powder in bulk from India, or importing from an undenatured Type II collagen manufacturer and exporter, can request these items from the supplier before approving a purchase.
What Should Nutraceutical Formulators Look For?
Look past the ingredient name when assessing an undenatured Type II collagen ingredient.
1. Clinical Evidence
Check whether published clinical work covers the exact ingredient or a well-characterised equivalent. Evidence tied to the specific ingredient supports both product development and technical communication more firmly.
2. Structural Preservation
The functional rationale rests on native characteristics, so ask how the supplier keeps processing conditions under control.
3. Consistent Specifications
Nutraceutical production depends on consistent batches. A dependable supplier provides clear specifications and suitable quality documentation.
4. Dose Efficiency
A low daily dose opens the door to capsules, tablets, sachets, gummies and other formats. The Unstergen® study used 40 mg per day for 90 days, a useful clinical reference for this ingredient, but not a universal dose for every Type II collagen product.
5. Regulatory Support
Ingredient approval, claims and labelling rules differ between markets, so technical and regulatory paperwork can matter as much as the nutritional specification.
What Should Nutraceutical Formulators Look For?
Look past the ingredient name when assessing an undenatured Type II collagen ingredient.
1. Clinical Evidence
Check whether published clinical work covers the exact ingredient or a well-characterised equivalent. Evidence tied to the specific ingredient supports both product development and technical communication more firmly.
2. Structural Preservation
The functional rationale rests on native characteristics, so ask how the supplier keeps processing conditions under control.
3. Consistent Specifications
Nutraceutical production depends on consistent batches. A dependable supplier provides clear specifications and suitable quality documentation.
4. Dose Efficiency
A low daily dose opens the door to capsules, tablets, sachets, gummies and other formats. The Unstergen® study used 40 mg per day for 90 days, a useful clinical reference for this ingredient, but not a universal dose for every Type II collagen product.
5. Regulatory Support
Ingredient approval, claims and labelling rules differ between markets, so technical and regulatory paperwork can matter as much as the nutritional specification.
Formulation Opportunities for Joint Supplements
Several product concepts suit undenatured Type II collagen.
Targeted Joint-Health Supplements
Capsules and tablets remain the established formats for joint products.
Healthy-Ageing Products
Joint mobility is tied to active ageing and quality of life, which leaves room for wider healthy-ageing products.
Active-Lifestyle and Mobility Products
Products for active consumers can include joint ingredients as part of a broader mobility offer.
Combination Formulations
Options to assess alongside it include hyaluronic acid, chondroitin, glucosamine, MSM, calcium, vitamin D and botanical extracts. The right mix depends on the concept and on the evidence.
The goal is not to pile in as many joint ingredients as possible. Build evidence-led combinations in which each component has a distinct role, and check dose, compatibility, stability, sensory qualities and regulation along the way.
From Ingredient to Product Differentiation
The nutraceutical shelf is crowded with similar ingredient combinations, so standing out takes more than printing the word collagen on a label.
Undenatured Type II collagen offers several points of difference:
- Specific collagen type: Type II is clearly linked to articular cartilage.
- Distinct processing: native structure is deliberately kept.
- Targeted mechanism: a proposed oral tolerance route unlike that of collagen peptides.
- Low-dose potential: the Unstergen® study used 40 mg per day.
- Human clinical evidence: the Unstergen® ingredient itself was tested in a randomised, double-blind, placebo-controlled study.
Together, these points give a more technical and differentiated B2B proposition.
Evidence-Led Marketing: How Brands Should Word Their Claims
Responsible communication is essential for brands and ingredient suppliers.
Steer away from bold promises like “repairs damaged cartilage” or “cures osteoarthritis”. Wording that fits the evidence better includes:
- Targeted joint support with undenatured Type II collagen
- A clinically studied joint ingredient for comfort and mobility
- Native Type II collagen for modern joint blends
- A science-backed functional ingredient for today’s joint supplements
Every claim must finally be checked against the rules of the market where the product is sold.
The Opportunity for Manufacturers and Brands
Three forces will probably shape the next wave of joint products: clinical evidence, ingredient differentiation and efficient formulation. Undenatured Type II collagen sits where all three meet.
Ingredient manufacturers can move beyond commodity collagen and offer a specialised functional ingredient. Nutraceutical brands can build more targeted joint products. Contract manufacturers get another distinctive choice for capsules, tablets, powders and further supplement formats.
The Unstergen® paper adds human data for this particular ingredient. Taking 40 mg daily for 90 days, participants showed larger gains than placebo in WOMAC, pain, quality of life and investigator-rated X-ray findings. The authors call it a proof-of-concept study and ask for larger trials.
That balance matters. An ingredient earns its value by tying together identity, mechanism, manufacturing quality, clinical data and formulation use, not by making the boldest possible claim.
Conclusion: Undenatured Type II Collagen for Joint Supplements
Undenatured Type II collagen gives brands a differentiated way into the expanding market for joint nutraceuticals. Unlike hydrolysed collagen peptides, it is designed to keep native structural features linked to its proposed oral tolerance mechanism, which gives formulators a functional ingredient with its own scientific logic.
Unstergen®, made from chicken sternum cartilage, was assessed in a 2025 human study that gives encouraging results. Over 90 days, in a randomised, double-blind, placebo-controlled proof-of-concept design, a 40 mg daily dose coincided with a 20.39% drop in WOMAC score and a 37.77% drop in pain NRS, versus smaller drops with placebo. Better quality of life and investigator-rated X-ray findings were reported too, and the study recorded no serious adverse events and none linked to the intervention.
For B2B manufacturers, the point is not just to add another collagen to a formula, but to build targeted, evidence-led joint products on one clearly differentiated functional ingredient.
As consumers grow better informed and demand for clinically supported nutraceuticals rises, undenatured Type II collagen can play a real part in the next wave of joint supplements.
About Titan Biotech Ltd.: Undenatured Type II Chickedn Collagen Manufacturer and Exporter
Titan Biotech Ltd. is a BSE-listed manufacturer and exporter of biological raw material ingredients. The company produces collagen and proteins, ox bile extracts, chelated minerals and botanical extracts for pharmaceutical, nutraceutical, cosmetic, animal nutrition, veterinary, food and beverage and biotechnology industries, and supplies customers in more than 100 countries.
As an undenatured Type II chicken collagen manufacturer, supplier and exporter, Titan Biotech Ltd. offers Unstergen®, an undenatured chicken collagen Type II ingredient derived from chicken sternum cartilage. Unstergen® was evaluated in a 90 day randomized, double-blind, placebo-controlled proof-of-concept study at 40 mg/day in adults with osteoarthritis. Titan Biotech Ltd. works with B2B buyers in India and global markets, including nutraceutical brands, supplement companies and contract manufacturers.
Frequently Asked Questions About Undenatured Type II Collagen
Q1. What is undenatured Type II collagen?
It is a collagen ingredient whose processing preserves the key features of native Type II collagen. It suits joint products well, since articular cartilage contains a large share of Type II collagen.
Q2. How is undenatured Type II collagen different from hydrolysed collagen?
Hydrolysed collagen is broken into small peptides, whereas undenatured Type II collagen keeps its native structure. That gives them different mechanisms and different roles in a formula.
Q3. What is Unstergen®?
Unstergen® is the brand name Titan Biotech Limited uses for its undenatured chicken collagen Type II, sourced from chicken sternum cartilage. A published human trial, randomised, double-blind and placebo-controlled, has examined it.
Q4. What dose of Unstergen® was studied?
In the published study, adults with osteoarthritis took 40 mg daily for 90 days. That is the dose tested for Unstergen®, so it should not be copied across to other undenatured Type II collagen products as a general recommendation.
Q5. What clinical benefits were reported?
Unstergen®users saw bigger drops in WOMAC and pain NRS than the placebo group, along with better quality of life and better investigator-rated X-ray findings.
Q6. Can undenatured Type II collagen be combined with other joint ingredients?
Yes, It can be assessed with hyaluronic acid, chondroitin, glucosamine, MSM or vitamin D, depending on the product concept, compatibility and regulatory rules.
Q7. Is undenatured Type II collagen suitable for healthy-ageing supplements?
Yes, it can be considered for healthy-ageing and mobility products, since comfortable joints are part of staying active with age. Keep product claims in line with the evidence and local rules.
Q9. Is Unstergen® clinically proven to cure osteoarthritis?
No, The study positions Unstergen® as a possible supportive option and says larger trials are needed. It must not be marketed as a cure for osteoarthritis or as a substitute for medical care.
Q10. Who is a reliable undenatured Type II collagen manufacturer in India?
Titan Biotech Ltd., based in Delhi, is an India based manufacturer and exporter of undenatured Type II chicken collagen under the Unstergen® brand.
Primary Clinical Reference
Sriraam VT, Pillai S, Singla R, Singla S. Clinical benefits of undenatured chicken collagen type II Unstergen® as a nutritional therapy in the management of osteoarthritis: a double-blind, placebo controlled clinical study. International Journal of Research in Orthopaedics. 2025;11(3):505–512.
